Gastric Cancer Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Test, Fluorescent in situ hybridization ), By Product, By Gastric Cancer Type, and Carcinoid Tumor), By End User, and Region Forecast 2019-2030
Gastric Cancer Testing Market size was valued at US$ 2.6 billion in 2023 and is expected to grow at a significant CAGR of 17.9% from 2024-2030. Cancer begins in the body when the cells in the body grow without any control. Cells present in any part of the body can develop cancer, which tend to spread to the other parts of the body. Gastric cancer is a type of cancer that starts in the stomach. The gastric cancer is also called as the stomach cancer. The progression of this cancer is slow. The advancement in the growth of the tumor leads serious complications. The treatment depends on the stage of the cancer. The early diagnosis helps in improving the survival rates.
Cancer is caused by uncontrolled abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumour, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer. Indigestion and stomach pain or discomfort are signs of gastric cancer. The global gastric cancer testing market is expected to develop due to an increase in the incidence of gastrointestinal tumours, lymphoma, and adenocarcinoma, as well as an increase in alcohol use, smoking, and the geriatric population. However, the global market is expected to be hampered by tight government regulations and high testing costs.
Study Period
2024-2030Base Year
2023CAGR
17.9%Largest Market
Asia PacificFastest Growing Market
North America
Increase in the prevalence of gastrointestinal tumors, adenocarcinoma, lymphoma etc. and change in the lifestyles are majorly driving the growth of the gastric cancer testing market. Various factors such as increasing alcohol consumption and smoking is anticipated to drive the growth of the gastric cancer testing market.
However, the stringent government regulations for the approval would hamper the growth of the market. The high cost involved in the testing would restrain the growth of the gastric cancer testing market.
Asia Pacific gastric cancer testing market is the dominant market when compared with that of the other regional markets. According to the World Cancer Research Fund International, Japan has held the largest share of around 24.7% in the global stomach cancer treatment market owing to its higher consumption of the spicy and salty food. Also, the other countries such as China which accounted for about 29.9% and South Korea which accounted for 41.4% has higher rates of incidence in the stomach cancer.
According to the World Health Organization (WHO), there are 723,000 cancer related deaths caused by the stomach cancer all across the globe. The North America and the European region are expected to grow at slow pace over the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 2.6 billion |
|
Market CAGR |
17.9% |
|
By Test |
|
|
By Product |
|
|
By Gastric Cancer Type |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The Global gastric cancer testing market size was valued at US$ 2.6 billion in 2023 and is projected to grow at a significant CAGR of 17.9% from 2024 to 2030.
The key segments covered in the restless leg’s syndrome market are technology, components, application, and end-users.
The gastric cancer testing market key players are Agilent Technologies Inc (U.S), Thermo Fisher Scientific Inc (U.S), Illumina Inc (Denmark), Becton, Dickinson and Company (U.S), GE Healthcare (U.K), QIAGEN N.V (Netherlands), Abbott Laboratories Inc (U.S), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K), R. Bard Inc (U.S)
| 1.Executive Summary |
| 2.Global Gastric Cancer Testing Market Introduction |
| 2.1.Global Gastric Cancer Testing Market - Taxonomy |
| 2.2.Global Gastric Cancer Testing Market - Definitions |
| 2.2.1.Test |
| 2.2.2.Product |
| 2.2.3.Gastric Cancer Type |
| 2.2.4.End User |
| 2.2.5.Region |
| 3.Global Gastric Cancer Testing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Gastric Cancer Testing Market Analysis, 2019-2023 and Forecast 2024-2030 |
| 4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Gastric Cancer Testing Market By Test, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 5.1. Immunohistochemistry (IHC) |
| 5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Fluorescent in situ hybridization (FISH) |
| 5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Gastric Cancer Testing Market By Product, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 6.1. Kits |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Reagents |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Gastric Cancer Testing Market By Gastric Cancer Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 7.1. Adenocarcinoma |
| 7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Lymphoma |
| 7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Gastrointestinal stromal tumor (GIST) |
| 7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Carcinoid tumor |
| 7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Gastric Cancer Testing Market By End User, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Diagnostic centers |
| 8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Others |
| 8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Gastric Cancer Testing Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Gastric Cancer Testing Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 10.1. Test Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Immunohistochemistry (IHC) |
| 10.1.2.Fluorescent in situ hybridization (FISH) |
| 10.2. Product Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Kits |
| 10.2.2.Reagents |
| 10.3. Gastric Cancer Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Adenocarcinoma |
| 10.3.2.Lymphoma |
| 10.3.3.Gastrointestinal stromal tumor (GIST) |
| 10.3.4.Carcinoid tumor |
| 10.4. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Diagnostic centers |
| 10.4.3.Others |
| 10.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Gastric Cancer Testing Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 11.1. Test Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Immunohistochemistry (IHC) |
| 11.1.2.Fluorescent in situ hybridization (FISH) |
| 11.2. Product Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Kits |
| 11.2.2.Reagents |
| 11.3. Gastric Cancer Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Adenocarcinoma |
| 11.3.2.Lymphoma |
| 11.3.3.Gastrointestinal stromal tumor (GIST) |
| 11.3.4.Carcinoid tumor |
| 11.4. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Diagnostic centers |
| 11.4.3.Others |
| 11.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12.Asia Pacific (APAC) Gastric Cancer Testing Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 12.1. Test Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Immunohistochemistry (IHC) |
| 12.1.2.Fluorescent in situ hybridization (FISH) |
| 12.2. Product Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Kits |
| 12.2.2.Reagents |
| 12.3. Gastric Cancer Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Adenocarcinoma |
| 12.3.2.Lymphoma |
| 12.3.3.Gastrointestinal stromal tumor (GIST) |
| 12.3.4.Carcinoid tumor |
| 12.4. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Diagnostic centers |
| 12.4.3.Others |
| 12.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Gastric Cancer Testing Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 13.1. Test Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Immunohistochemistry (IHC) |
| 13.1.2.Fluorescent in situ hybridization (FISH) |
| 13.2. Product Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Kits |
| 13.2.2.Reagents |
| 13.3. Gastric Cancer Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Adenocarcinoma |
| 13.3.2.Lymphoma |
| 13.3.3.Gastrointestinal stromal tumor (GIST) |
| 13.3.4.Carcinoid tumor |
| 13.4. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Diagnostic centers |
| 13.4.3.Others |
| 13.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Gastric Cancer Testing Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 14.1. Test Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Immunohistochemistry (IHC) |
| 14.1.2.Fluorescent in situ hybridization (FISH) |
| 14.2. Product Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Kits |
| 14.2.2.Reagents |
| 14.3. Gastric Cancer Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Adenocarcinoma |
| 14.3.2.Lymphoma |
| 14.3.3.Gastrointestinal stromal tumor (GIST) |
| 14.3.4.Carcinoid tumor |
| 14.4. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Diagnostic centers |
| 14.4.3.Others |
| 14.5. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Agilent Technologies Inc (U.S) |
| 15.2.2.Thermo Fisher Scientific Inc (U.S) |
| 15.2.3.Illumina Inc (Denmark) |
| 15.2.4.Becton, Dickinson and Company (U.S) |
| 15.2.5.GE Healthcare (U.K) |
| 15.2.6.QIAGEN N.V (Netherlands) |
| 15.2.7.Abbott Laboratories Inc (U.S) |
| 15.2.8.Roche Diagnostics (Switzerland) |
| 15.2.9.Siemens Healthcare (Germany) |
| 15.2.10.Philips Healthcare (U.K) |
| 15.2.11.R. Bard Inc (U.S) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
